Cystic Fibrosis Frequently Asked Questions: Question 4: What is the appropriate duration of therapy for respiratory exacerbations in Cystic Fibrosis patients infected with Pseudomonas aeruginosa?

Paediatr Respir Rev. 2016 Jan:17:60-2. doi: 10.1016/j.prrv.2015.03.004. Epub 2015 Apr 23.

Authors

Kathryn M Sutton¹, Dominic A Fitzgerald²

Affiliations

¹ Sydney University Medical School, Discipline of Paediatrics and Child Health, University of Sydney.
² Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; Sydney Medical School, Discipline of Paediatrics and Child Health, University of Sydney, NSW, Australia. Electronic address: dominic.fitzgerald@health.nsw.gov.au.

PMID: 25982382
DOI: 10.1016/j.prrv.2015.03.004

No abstract available

MeSH terms

Administration, Inhalation
Administration, Intravenous
Administration, Oral
Anti-Bacterial Agents / administration & dosage*
Cystic Fibrosis / drug therapy*
Disease Progression
Drug Administration Schedule
Humans
Pseudomonas Infections / drug therapy*
Pseudomonas aeruginosa
Time Factors

Substances

Anti-Bacterial Agents